tbuckley/cabot-search huggingface dataset:
Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study
Authors: M.S. Van der Heijden, Y. Loriot, I. Duran, A. Ravaud, M.M. Retz, N.J. Vogelzang, B. Nelson, J. Wang, X. Shen, T. Powles
Journal: Annals of Oncology (2019)
Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience
Authors: Al-Ola Abdallah, Neil Dunavin, Brian McClune, Leyla Shune, Ajoy L. Dias, Zahra Mahmoudjafari, Erica Hochard, Joseph P. McGuirk, Siddhartha Ganguly
Journal: Blood (2018)
A Measured Dose of Optimism for the Evolution of ICU-Based Palliative Care
Authors: Christopher E. Cox, May Hua, David Casarett
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Authors: M. Hussain, J. Mateo, K. Fizazi, F. Saad, N.D. Shore, S. Sandhu, K.N. Chi, O. Sartor, N. Agarwal, D. Olmos, A. Thiery-Vuillemin, P. Twardowski, N. Mehra, C. Goessl, J. Kang, J. Burgents, W. Wu, A. Kohlmann, C.A. Adelman, J. de Bono
Journal: Annals of Oncology (2019)
Abstract 15187: Atrial High Rate Episodes in Pacemaker Patients and Risk of Cognitive Decline: Unmask and Prevent Atrial Fibrillation Consequences
Authors: Juan Benezet-Mazuecos, Jose Antonio Iglesias, Marcelino Cortes, Juan Jose de la Vieja, Esmeralda Serrano, Pepa Sanchez-Borque, Angel Miracle, Jose Manuel Rubio, Jeronimo Farre
Journal: Circulation (2016)

Introduction: Atrial fibrillation (AF) has been linked with an increased risk of cognitive impairment. The mechanism is unknown, but chronic microembolism resulting in silent ischemic brain lesions...
Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Authors: R. Laza-Briviesca, A. Cruz-Bermudez, M. Casarrubios, E. Nadal, M A Insa Molla, M.-R. García-Campelo, G. Huidobro, M Domine Gomez, M Majem Tarruella, D Rodriguez Abreu, A. Martinez-Marti, JCastro De Carpeno, M Cobo Dols, G López Vivanco, E. del Barco Morillo, R. Bernabé, N. Viñolas, I C Barneto Aranda, B Massuti Sureda, M. Provencio
Journal: Annals of Oncology (2019)
A platform trial with a registry study for rare cancers: MASTER KEY project
Authors: S.N. Narita, H.S. Okuma, K. Yonemori, T. Sukigara, A. Hirakawa, W. Munakata, N. Okita, T. Shimizu, T. Shibata, A. Kawai, N. Yamamoto, K. Izutsu, M. Muto, H. Akita, E. Baba, K. Nakamura, H. Mano, T. Nishida, Y. Fujiwara
Journal: Annals of Oncology (2019)
Acquired Chromosomal Abnormalities t(14;16), Del(17p) or Del(13q) after Receiving Chemotherapies Predict the Poor Prognosis of Multiple Myeloma
Authors: Hirofumi Yamauchi, Yuko Mishima, Masahiro Yokoyama, Noriko Nishimura, Yoshiharu Kusano, Norihito Inoue, Anna Nishihara, Yasuhito Terui, Kiyohiko Hatake
Journal: Blood (2017)
Effect of chemotherapy on fatigue and presence of TNF- in breast cancer patients.
Authors: Fernando Affonso Fonseca, Felipe Melo Cruz, Tatiana Goberstein Lerner, Daniel Iracema Cubero, Beatriz da Costa Aguiar Alves, Flavia Souza, Renata Kunyioshi, Auro Del Giglio
Journal: Journal of Clinical Oncology (2013)

e20601 Background: Chemoterapy induced fatigue (CRF) is a common complain and few studies assessed so far the role of inflammatory biomarkers as predictors of CRF. OBJECTIVE: The primary objective of our study is to evaluate potential biomarkers of CRF in breast cancer (BC) patients receiving adjuvant Chemotherapy (CHT). Methods: Thirty-seven localized BC patients (clinical stages I-III) consecutively treated at the oncology service of Faculdade de Medicina da Fundação ABC were enrolled in this study. All patients received doxorubicin and cyclophosphamide based chemotherapy. Before the beginning of chemotherapy and before the second cycle, all patients answered the BFI (Brief Fatigue Inventory) questionnaire. The following inflammatory markers were collected: C-reactive protein (CRP), tumor necrosis Factor alpha (TNF-α) and interleukin 6 (IL-6). We correlated these inflammatory markers with BFI scores of each patient before and after cycle 1 and cycle 2 of chemotherapy. Results: The mean values of the inflammatory markers were: CRP 4.58 mg/dL (IC 95% 3.17-5.90), TNF-α 11 mg/dL ( IC 95% 8.84-13.79) and IL-6 3.74 (IC 95% 1.93-5.54). We observed a positive correlation between the BFI scores and TNF-α (p=0.0201). Conclusions: TNF-α may represent a potential CRF biomarker. Future studies may elucidate the potential usefulness of TNF-α for monitoring the anti-fatigue effects of new drugs for the treatment of CRF.
WGS implementation in standard cancer diagnostics for every cancer patient (WIDE)
Authors: P. Roepman, L. Bosch, K. Samsom, L. Schipper, E. de Bruijn, L. Hoes, I. Riethorst, L. Schoenmaker, L. van der Kolk, H. van Snellenberg, E.E. Voest, E. Cuppen, K. Monkhorst, G. Meijer
Journal: Annals of Oncology (2019)
ACHIEVE-2 trial: A randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC)
Authors: T. Yoshino, T. Yamanaka, M. Shiozawa, D. Manaka, M. Kotaka, M. Gamoh, A. Shiomi, A. Makiyama, Y. Munemoto, T. Rikiyama, M. Fukunaga, T. Ueki, K. Shitara, H. Shinkai, N. Tanida, K. Yamazaki, E. Sunami, A. Ohtsu, Y. Maehara
Journal: Annals of Oncology (2019)
Simplified steps to heterologous prime-boost HIV vaccine development?
Authors: Nelson L. Michael
Journal: Journal of Clinical Investigation (2019)

The RV 144 HIV vaccine efficacy study showed a reduction in HIV-1 infection risk in Thai volunteers who received two priming vaccinations of vCP1521 ALVAC (attenuated recombinant canarypox virus expressing HIV group-specific antigen, polymerase, and envelope genes) followed by two additional ALVAC vaccinations and coadministration of purified bivalent gp120 proteins (AIDSVAX B/E). In this issue of the JCI, Rouphael et al. build on these results by substituting a DNA plasmid cocktail expressing HIV-1 subtype C group-specific antigen, polymerase, and envelope antigen genes (DNA-HIV-PT123) for ALVAC in a phase 1b safety and immunogenicity study. The results indicate that the vaccine regimen is safe, elicits promising cross-subtype humoral and cellular responses, and opens up potentially simplified approaches to HIV-1 vaccine development.
Antibody-mediated targeting of TNFR2 activates CD8 <sup>+</sup> T cells in mice and promotes antitumor immunity
Authors: Eric M. Tam, Ross B. Fulton, James F. Sampson, Marco Muda, Adam Camblin, Jennifer Richards, Alexander Koshkaryev, Jian Tang, Vinodh Kurella, Yang Jiao, Lihui Xu, Kathy Zhang, Neeraj Kohli, Lia Luus, Elizabeth Hutto, Sandeep Kumar, James Lulo, Violette Paragas, Christina Wong, James Suchy, Stephanie Grabow, Anne-Sophie Dugast, Hong Zhang, Fabien Depis, Sonia Feau, Aniela Jakubowski, Wenlian Qiao, Galina Craig, Maja Razlog, James Qiu, Yu Zhou, James D. Marks, Michael Croft, Daryl C. Drummond, Andreas Raue
Journal: Science Translational Medicine (2019)

Anti-TNFR2 antibodies induce costimulation of T cells, complete tumor regression, and immune memory in mice and can be combined with anti-PD1.
Exercise level, interest and preferences in cancer patients
Authors: A. Avancini, V.M. Pala, V. Krogh, S. Sieri, L. Mariani, D. Tregnago, G. Sartori, I. Trestini, E. Bria, M. Milella, M. Lanza, S. Pilotto
Journal: Annals of Oncology (2019)
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Authors: T. Yau, J.W. Park, R.S. Finn, A.-L. Cheng, P. Mathurin, J. Edeline, M. Kudo, K.-H. Han, J.J. Harding, P. Merle, O. Rosmorduc, L. Wyrwicz, E. Schott, S.P. Choo, R.K. Kelley, D. Begic, G. Chen, J. Neely, J. Anderson, B. Sangro
Journal: Annals of Oncology (2019)
FRI-175-Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study
Authors: Svenja Hardtke, Heiner Wedemeyer, Florin Alexandru Caruntu, Manuela Curescu, Yalcin Kendal, Ulus Akarca, Esra Yurdcu, Selim Gurel, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George Papatheodoridis, Onur Keskin, Kerstin Port, Monica Radu, Fehmi Tabak, Ramazan Idilman, Mithat Bozdayi, Armin Koch, Michael P. Manns, Markus Cornberg, Cihan Yurdaydin
Journal: Journal of Hepatology (2019)
Influence of genetic variation in COMT on cisplatin-induced nephrotoxicity in cancer patients
Authors: B.C. Agema, S.L. Koolen, M. De With, N. Heersche, N. van Doorn, E. Oomen-de Hoop, S. Visser, J.G. Aerts, S. Bins, R.H.N. van Schaik, R.H. Mathijssen
Journal: Annals of Oncology (2019)
Association Between Rotavirus Vaccination and Risk of Intussusception Among Neonates and Infants
Authors: Hai-Ling Lu, Ying Ding, Hemant Goyal, Hua-Guo Xu
Journal: JAMA Network Open (2019)

<h3>Importance</h3> The conclusions from the multiple randomized clinical trials exploring the relationship between development of intussusception and rotavirus vaccination among neonates and infants have been controversial. <h3>Objective</h3> To evaluate the association between rotavirus vaccination and risk of intussusception. <h3>Data Sources</h3> For this systematic review and meta-analysis, PubMed, Web of Science, Cochrane library, and Embase databases were searched from January 1, 1999, through December 31, 2018, using no language restrictions. The search terms were<i>rotavirus</i>or<i>RV</i>(rotavirus vaccine) or<i>HRV</i>(human rotavirus vaccine),<i>vaccin*</i>, and<i>intussusception</i>. <h3>Study Selection</h3> Randomized clinical trials of neonates and infants that compared the risk of intussusception after the vaccination with a placebo group were included. <h3>Data Extraction and Synthesis</h3> A fixed-effects model was used to pool the data. Statistical heterogeneity was assessed with Q test and<i>I</i><sup>2</sup>statistic; relative risk (RR), risk difference (RD), and 95% CIs were calculated using the Mantel-Haenszel method. <h3>Main Outcomes and Measures</h3> The main outcome was the diagnosis of intussusception in the analysis. The pooled and subtotal results of RR, RD, and 95% CI for the risk of intussusception were estimated at 31 days, 1 year, and 2 years after vaccination. <h3>Results</h3> A total of 25 randomized clinical trials including 200 594 participants (104 647 receiving vaccine and 95 947 receiving placebo) in 33 countries from 4 continents were included in this meta-analysis. Twenty cases of definite intussusception were diagnosed within 31 days after rotavirus vaccination, with 11 cases (55%) in the vaccine group and 9 cases (45%) in the placebo group (RD, 0.17 per 10 000 infants [95% CI, −1.16 to 1.50 per 10 000 infants],<i>P</i> = .80; RR, 1.14 [95% CI, 0.49 to 2.64],<i>P</i> = .77). Seventy-four cases were reported within 1 year, with 37 cases (50%) in the vaccine group and 37 cases (50%) in the placebo group (RD, −0.65 per 10 000 infants [95% CI, −2.68 to 1.39 per 10 000 infants],<i>P</i> = .53; RR, 0.84 [95% CI, 0.53 to 1.32],<i>P</i> = .45). Fifty-nine cases were reported within 2 years, with 29 cases (49%) in the vaccine group and 30 cases (51%) in the placebo group (RD, −0.48 per 10 000 infants [95% CI, −3.64 to 2.69 per 10 000 infants],<i>P</i> = .77; RR, 0.91 [95% CI, 0.55 to 1.52],<i>P</i> = .73). <h3>Conclusions and Relevance</h3> Results of this systematic review and meta-analysis suggest that monovalent, pentavalent, monovalent human-bovine, oral bovine pentavalent, and human neonatal rotavirus vaccination was not associated with an elevated risk of intussusception among neonates or infants.
Measuring the cancer burden in Europe: The European Cancer Information System (ECIS)
Authors: M. Bettio, R.N. Carvalho, N. Dimitrova, T. Dyba, M. Flego, F. Giusti, C. Martos, L. Neamtiu, N. Nicholson, G. Randi, C. Nicholl
Journal: Annals of Oncology (2019)
Solid Tumors in Patients with Chronic Lymphocytic Leukemia Who Received Frontline Lenalidomide Therapy: Distribution and Clinical Outcomes
Authors: Ahmad Alhuraiji, Lorenzo Falchi, Michael Keating, Zeev Estrov, Paolo Strati, William Wierda, Nitin Jain, Philip A Thompson, Alessandra Ferrajoli
Journal: Blood (2016)
A window of opportunity trial of atorvastatin targeting p53 mutant malignancies
Authors: J.C. Baranda, A. Bur, T. Tsue, L. Shnayder, K. Kakarala, M. Telfah, T. Lin, S.K. Williamson, M. Al-Kasspooles, J. Ashcraft, N. Lakis, R. Madan, Q. Khan, A. Saeed, G. Reed, S. Weir, A. Godwin, S. Thomas, T. Komiya, T. Iwakuma
Journal: Annals of Oncology (2019)
Abstract #5455: Interindividual variability in fulvestrant sulfation by human liver cytosols : effect of sult 1a1 genotype on fulvestrant sulfation
Authors: Vineetha Koroth Edavana, suzanne Williams, David Caldwell, Baitang Ning, Xinfeng Yu, Kelly Mercer, Fred Kadlubar, Susan Kadlubar
Journal: Cancer Research (2009)

Fulvestrant (Faslodex\#8482;) is used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women. Fulvestrant is a pure antiestrogen that has been shown to directly down-regulate the expression of the estrogen receptor. In in vivo and in vitro breast cancer models, fulvestrant has anticancer activity equivalent to tamoxifen and is superior to tamoxifen in some models. Previous studies have demonstrated that fulvestrant metabolism in human, involves multiple drug metabolizing enzyme families, including the cytochromes P450 and UDP-glucuronosyltransferases. To date, however, fulvestrant sulfation has not been characterized. We examined sulfation of fulvestrant using recombinant sulfotransferase (SULT) isoforms (SULT1A1, 1A3, 1B1, 1C1, 1C2, 1E1, 2A1, 2B1a and 2B1b). Of these isoforms, SULT1A1, which is the most widely expressed SULT, displayed the highest sulfating activity. We next examined expression of SULTs in laser capture microdissected breast tumors using qRT-PCR and found that SULT1A1, along with SULT2B1b, were the most highly expressed SULTs in breast tumors. SULT1A1 is also highly expressed in human liver; therefore we assayed fulvestrant sulfation in human liver cytosols from 100 individuals. There was wide interindividual variability in fulvestrant-sulfation capacity. Fulvestrant sulfation was significantly correlated with \#946;-naphthol sulfation (r=0.76, p  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5455.
The discovery of RNA-aptamers that selectively bind and inhibit glioblastoma stem cells by targeting EphA2
Authors: A. Affinito, C. Quintavalle, C.L. Esposito, G. Roscigno, C. Vilardo, S. Nuzzo, L. Ricci Vitiani, G. De Luca, Z. Minic, S. Giannetti, R. Pallini, M.V. Berezovski, A.S. Kichkailo, I.N. Lapin, V. De Franciscis, G. Condorelli
Journal: Annals of Oncology (2019)
<b><i>Candida albicans</i></b>in a Peripheral-Blood Smear
Authors: Erez Nadir, Miriam Kaufshtein
Journal: New England Journal of Medicine (2005)

An infant born at 26 weeks required intubation, catheterization of the umbilical artery and vein, and broad-spectrum antimicrobial agents. On the fifth postnatal day, the infant became clinically unstable.
Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)
Authors: M. Untch, C.E. Geyer, C. Huang, S. Loibl, N. Wolmark, M.S. Mano, G. von Minckwitz, A. Brufsky, X. Pivot, J. Polikoff, A. Fontana, B. Kaufman, J.C. Alcedo, T. Boulet, H. Liu, C. Song, E.P. Mamounas
Journal: Annals of Oncology (2019)
A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib
Authors: Richa Manwani, Oliver Cohen, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Darren Foard, Helen J. Lachmann, Cristina Quarta, Marianna Fontana, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar
Journal: Blood (2019)
Gastric cancer screening in BRCA 2 gene mutation carriers: Should it be recommended?
Authors: I.C. Oliveira, S. Fernandes, P. Pereira, S. Fragoso, S. Santos, P. Rodrigues, J. Parreira, P. Louro, I. Coelho, F. Rodrigues, A. Clara, A. Luís, F. Vaz
Journal: Annals of Oncology (2019)
Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
Authors: T. Vandenbroucke, M. Verheecke, M. van Gerwen, K. Van Calsteren, M. Halaska, M. Fumagalli, R. Fruscio, M. Veening, L. Lagae, P. Ottevanger, J.-U. Voigt, J. de Haan, M. Gziri, A. Gandhi, C. Maggen, L. Mertens, G. Naulaers, L. Claes, F. Amant
Journal: Annals of Oncology (2019)
Residual cancer burden as a prognostic factor in a large series of neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes
Authors: C. Falo, S. Fernández, E. Garrigós, A C Vethencourt Casado, S. Vázquez, A. Stradella, S. Recalde, M.J. Pla, M. Campos, A. Gumà, R. Ortega, A. Petit, T. Soler, J. Perez, E. Fernandez, M.S. Bergamino, S Pernas Simon, M.J. Gil, J. Ponce, A Garcia Tejedor
Journal: Annals of Oncology (2019)
Bordetella pertussis exhibits specific attachment, invasion, and cytotoxic capabilities toward human cancer cells.
Authors: John M. Pawelek, Stefano Sodi, James Platt, K. Brooks Low
Journal: Cancer Research (2004)

3762  In its normal life cycle, B. pertussis attaches to, and invades ciliated epithelia and macrophages of the human airways, using adhesins specialized for certain oligosaccharides and proteins on these cells. Here we report that B. pertussis uses similar mechanisms for invasion of a variety of human cancer cells in vitro, and exhibits potent, invasion-dependent, cytotoxicity. In a 30′ in vitro invasion assay, B. pertussis invaded human SKmel-23 melanoma cells at 20-30 times the rate for normal human melanocytes and fibroblasts. B. pertussis invasion of SKmel-23 cells was inhibited by preincubation of cancer cells with glycosidase F, the plant lectins LPHA and TGP, human antibodies vs CD15 and CD11b, or the RGD tripeptide sequence—implying that the structural requirements for invasion included β1,6-branched N-glycans, Lewis × antigens, CD11b, and the sequence arg-gly-asp respectivelly. Invasion was also inhibited by preincubation of cancer cells with 3-methyladenine (3-MA), indicating a role for phagolysosomal vacuole formation in uptake of B. pertussis by the cancer cells. When fixed, paraffin-embedded sections of human cancers were re-hydrated, incubated with B. pertussis, and then stained with LPHA for β1,6-branched N-glycans, bacteria were seen attached specifically to the sugar-rich regions of the tumors. Exposure of human SKmel-23 melanoma, MCF-7 breast carcinoma, or A549 lung carcinoma cells in culture to Bordetella pertussis caused marked morphological changes and massive lysis of the cells. Lysis was largely prevented by simultaneous treatment with 3-MA. B. pertussis targeted A549 human lung carcinomas growing s.c. in nu/nu mice. Regarding tumor growth, in an on-going experiment with A549 tumors, in the 8 saline-injected control mice, each individual tumor increased in size over 77 days with a mean 15-fold increase in mass. In contrast, of the 16 bacteria-injected mice, each tumor eventually ceased growing or decreased in mass, such that at 77 days after initiation of treatment, the mean tumor size was unchanged from the starting size, with several cases of regression and scarring. Regarding safety, i.v.-injected B. pertussis showed no toxicity toward the mice after repeated injections of the highest dose of bacteria tested (5 × 108 cfu/mouse). Thus for a number of reasons, B. pertussis appears to be a promising new anticancer vector.
Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs. outpatient) at diagnosis
Authors: D. Muñoz Guglielmetti, D. Pesántez, F. Posch, C. Ay, M. Aramberri, M.D.C. Beato Zambrano, C. Diaz-Pedroche, C. Font
Journal: Annals of Oncology (2019)
Abstract MP06: Vitamin K Status and Cardiovascular Disease: A Participant-Level Meta-Analysis
Authors: M. Kyla Shea, Daniel E Weiner, Gregory Matuszek, Sarah L Booth, Emelia J Benjamin, Mary Cushman, Stephen B Kritchevsky, Gregory L Burke, Kathryn Barger
Journal: Circulation (2019)

Introduction: A role for vitamin K in CVD has been proposed because vitamin K-dependent proteins are present in vascular tissue. In individual cohorts, low vitamin K status has been associated with increased CVD. We conducted a participant-level meta-analysis to summarize the association between circulating vitamin K and CVD in the Framingham Offspring Study, the Health, Aging, and Body Composition Study (Health ABC), and the Multi-ethnic Study of Atherosclerosis (MESA), three cohorts in which circulating vitamin K measures and confirmed cardiovascular events are available. Aim: To determine the association between vitamin K status and CVD in community-dwelling adults, overall and according to CVD risk and known risk factors. Methods: Circulating phylloquinone (vitamin K1) was measured from baseline fasting blood samples in 3626 participants and categorized as ≤0.5 nM, &gt;0.5 - ≤1.0 nM and &gt;1.0 nM. Multivariable Cox proportional hazards models assessed the association between circulating phylloquinone and risk of a composite of CVD and mortality. Results: Among the 3626 participants, mean baseline age was 65±11 yrs; 45% were men and 65% white. There were 1436 composite events over a median of 15.4 years. Participants with circulating phylloquinone &lt; 0.5 nM had a 21% higher risk for CVD and mortality compared to those with &gt;1.0nM [HR(95%CI)=1.21(1.06, 1.38)]. When stratified according to baseline CVD risk and risk factors, those with circulating phylloquinone &lt; 0.5 nM had a 27%-82% higher risk for CVD and mortality outcomes compared to those with &gt;1.0 nM ( Table ). Conclusion: Lower circulating phylloquinone was independently associated with a higher risk for CVD and mortality in community-dwelling adults, and more so among those at risk for CVD. Additional studies are needed to confirm our findings and clarify if segments of the population can derive cardiovascular benefit from improving vitamin K status.
Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Authors: D. Hao, P.M. Ellis, S.A. Laurie, R.A. Juergens, M. Mates, P.A. Bradbury, M. Tsao, M. Tehfe, C.K. Kollmannsberger, J.R. Goffin, P. Wheatley-Price, J. Hilton, A.G. Robinson, P. Brown-Walker, D. Tu, M. Smoragiewicz, L.K. Seymour
Journal: Annals of Oncology (2019)